Artivion, Inc. (AORT)
Artivion, Inc. (AORT) specializes in the development, manufacturing, and distribution of medical devices and tissue products for cardiovascular and general surgical procedures. The company focuses on providing biologic tissue products used in heart valve replacements, vascular grafts, and other surgical interventions, emphasizing regenerative and preservation techniques.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 18, 2015 | $0.03 | 2015-12-09 | 2015-12-11 |
| September 18, 2015 | $0.03 | 2015-09-09 | 2015-09-11 |
| June 19, 2015 | $0.03 | 2015-06-10 | 2015-06-12 |
| March 20, 2015 | $0.03 | 2015-03-11 | 2015-03-13 |
| December 19, 2014 | $0.03 | 2014-12-10 | 2014-12-12 |
Dividends Summary
- Artivion, Inc. has issued 14 dividend payments over the past 3 years
- The most recent dividend was paid 3564 days ago, on December 18, 2015
- The highest dividend payed out to investors during this period was $0.03 per share
- The average dividend paid during this period was $0.03 per share.
Company News
Artivion reported strong Q2 2025 financial results, with non-GAAP EPS of $0.24, exceeding expectations and growing 243% year-over-year. Revenue reached $113.0 million, a 15% increase, and the company raised its full-year 2025 guidance.
Artivion, Inc. experienced a data breach on November 20-21, 2024, where an unauthorized third party accessed network files potentially containing sensitive personal information like Social Security Numbers and driver's license details.
In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Frank Takkinen Lake Street Raises Buy $30.00 $28.00 Rick Wise Stifel Raises Buy $25.00 $22.00 Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.com
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.